Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus

American Journal of Gastroenterology

Volumn 97, Issue 8, 2002, Pages 1888-1895

  Sampliner, Richard E ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; ENDOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; ESOPHAGUS PH; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; INTESTINE METAPLASIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING TEST;

BARRETT ESOPHAGUS; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 0036678111     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04267-3     Document Type: Review

References (116)

1. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
2. Columnar-lined lower esophagus. An acquired lesion with malignant predisposition
3. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans
4. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
5. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
6. Adenocarcinoma complicating columnar epithelial lined (Barrett's) esophagus
7. Barrett's esophagus. Comparison of benign and malignant cases
8. The spectrum of carcinoma arising in Barrett's esophagus
9. Analysis of adenocarcinoma in Barrett's esophagus utilizing a staging system
10. Surgical pathology of adenocarcinoma arising in Barrett's esophagus
11. Adenocarcinoma of the esophagogastric junction in Barrett's esophagus
12. Barrett's metaplasia the source of adenocarcinomas of the cardia?
13. Adenocarcinoma of the esophagus and/or gastric cardia
14. Short segment Barrett's esophagus. Clinical and histological features, associated endoscopic findings and associations with gastric intestinal metaplasia
15. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data
16. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy
17. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus
18. Correlation of oesophageal acid exposure with Barrett's oesophagus length
19. Prevalence of metaplasia at the gastroesophageal junction
20. Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction
21. Intestinal metaplasia of the gastric cardia
22. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and the gastric cardia
23. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
24. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus
25. GORE Consortium. Risk factors for Barrett's esophagus in community-based practice
26. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
27. Critical issues in the management of gastroesophageal reflux disease
28. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease
29. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years
30. Erosive esophagitis impairs accurate detection of Barrett's esophagus: A prospective randomized double blind study
31. Detection of Barrett's esophagus after endoscopic healing for erosive esophagitis
32. Barrett's esophagus
33. Early diagnosis of columnar lined esophagus: A new endoscopic criterion
34. A study to examine agreement between endoscopy and histology for the diagnosis of columnar lined (Barrett's) esophagus
35. In vivo staining with toluidine blue as an adjunct to the endoscopic detection of Barrett's esophagus
36. Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett's esophagus
37. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus
38. Methylene blue directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus
39. Methylene blue chromoendoscopy for detection of short segment Barrett's esophagus
40. Enhanced magnification endoscopy: A new technique to identify specialized intestinal metaplasia in Barrett's esophagus
41. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's esophagus
42. The esophageal z-line appearance correlates to the prevalence of intestinal metaplasia
43. Scanning electron microscopy of Barrett's epithelial and its correlation with light microscopy and mucin stains
44. Endoscopic surveillance of Barrett's esophagus
45. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients
46. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma
47. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus
48. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study
49. Prospective evaluation of intestinal metaplasia and dysplasia within the cardia of patients with Barrett's esophagus
50. Dysplasia in short segment Barrett's esophagus - A prospective 3 year follow-up
51. Prevalence and characteristics of Barrett's esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction
52. Effect of segment length on risk for neoplastic progression in patients with Barrett's esophagus
53. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus
54. Dysplasia in inflammatory bowel disease. Standardized classification with provisional clinical information
55. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
56. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: A reaffirmation
57. Treatment of Barrett's metaplasia by antireflux surgery and endoscopic laser ablation. Clinical experience in ten patients
58. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: Preliminary results
59. Photodynamic therapy for Barrett's esophagus: Clinical update
60. Photodynamic therapy in the management of Barrett's esophagus with dysplasia
61. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high dose omeprazole
62. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus
63. Only patients with dysplasia progress to adenocarcinoma in Barrett's esophagus
64. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low and high risk patient subsets
65. Prospective multivariate analysis of clinical, endoscopic, and histologic factors predictive of the development of Barrett's multifocal high grade dysplasia or adenocarcinoma
66. Long-term nonsurgical management of Barrett's esophagus with high grade dysplasia
67. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus
68. The diagnosis of low grade dysplasia in Barrett's esophagus and its implications for disease progression
69. Extent of high grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma
70. Endoscopic mucosal resection of early cancer and high grade dysplasia in Barrett's esophagus
71. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high grade dysplasia within Barrett's esophagus
72. Management of Barrett's esophagus. A national study of practice patterns and their cost implications
73. Practice patterns for surveillance of Barrett's esophagus in the United States
74. Impact of hospital volume on operative mortality for major cancer surgery
75. An endoscopic biopsy protocol can differentiate high grade dysplasia from early adenocarcinoma in Barrett's esophagus
76. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high grade dysplasia
77. Barrett's esophagus with high grade dysplasia
78. Early adenocarcinoma in Barrett's esophagus
79. Prevalence, management, and outcome of early adenocarcinoma(pT1) of the esophagogastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II)
80. Occult esophageal adenocarcinoma. Extent of disease and implications for effective therapy
81. Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction
82. Limited resection of early adenocarcinoma of Barrett's esophagus
83. An endoscopic biopsy protocol can differentiate high grade dysplasia from early adenocarcinoma in Barrett's esophagus
84. Optimizing endoscopic biopsy detection of early cancers in Barrett's high grade dysplasia
85. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization
86. Proliferating cell nuclear antigen in the assessment of Barrett's mucosa
87. Expansion of the Ki67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus
88. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma
89. DNA content in Barrett's esophagus and esophageal malignancy
90. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus
91. Evaluation of p53 protein expression in Barrett's esophagus by two parameter flow cytometry
92. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma. A follow-up study
93. p53 in Barrett's adenocarcinoma and high grade dysplasia
94. Flow-cytometric analysis of growth regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma
95. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: Biological and clinics variables
96. Cyclooxygenase-2 expression in human esophageal carcinoma
97. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
98. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma. Ex vivo induction by bile salts and acid exposure
99. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression
100. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low and high risk patient subsets
101. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasiafree Barrett's esophagus. Thirteen year follow-up study on a cohort of patients
102. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus
103. Functional foregut abnormalities in Barrett's esophagus
104. Role of acid and duodenogastroesophageal reflux disease
105. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus
106. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor
107. Laparoscopic antireflux surgery in the treatment of gastroesophageal reflux disease in patients with Barrett's esophagus
108. Fundoplication provides effective and durable symptom relief in patients with Barrett's esophagus
109. Regression of Barrett's esophagus: The role of acid suppression, surgery and ablative methods
110. Prevalence of columnar lined (Barrett's) esophagus
111. Esophageal acid sensitivity in Barrett's esophagus
112. Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium
113. Partial regression of Barrett's esophagus by long term therapy with high dose omeprazole
114. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomised double blind study
115. Effect of antiinflammatory drugs on overall risk of common cancer: Case control study in general practice research database
116. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer